STOCK TITAN

Enlivex proposes raising authorized shares to 95M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Enlivex Ltd. is seeking shareholder approval to increase its authorized share capital from NIS 950,000,000, divided into 9,895,833 ordinary shares, to NIS 9,120,000,000, divided into 95,000,000 ordinary shares, and amend Article 2.1 of its Articles of Association. The proposal will be considered at an extraordinary meeting on December 4, 2026; shareholders of record as of November 20, 2026 may vote. Issued and outstanding shares totaled 1,532,077 as of November 10, 2026.

The board unanimously recommends voting “FOR.” The proposed increase would not itself affect the rights of current ordinary shareholders, but Enlivex says potential future share or convertible-security issuances could dilute voting power, market price or book value per share. Approval requires a majority of ordinary shares represented and voting, excluding abstentions.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed 95,000,000 authorized ordinary shares; future issuances could dilute holders.

Filing Explained

The proposed expansion remains pending a December 4, 2026 vote; as of November 10, 2026, 8,255,107 shares were already unissued, unreserved and available under the current authorization, alongside 77,867 reserved for equity plans and 30,782 for warrants.

Proposed authorized share capital NIS 9,120,000,000 Proposed for shareholder approval at the December 4, 2026 meeting
Proposed authorized ordinary shares 95,000,000 shares Proposed count if shareholders approve the increase
Current authorized share capital NIS 950,000,000 Current amount described in the proposal
Current authorized ordinary shares 9,895,833 shares Current count described in the proposal
Issued and outstanding ordinary shares 1,532,077 shares As of November 10, 2026
Shares reserved under incentive plans 77,867 shares As of November 10, 2026; includes shares underlying outstanding options and RSUs
Shares reserved for outstanding warrants 30,782 shares As of November 10, 2026
Unissued, unreserved shares available for future issuances 8,255,107 shares As of November 10, 2026
authorized share capital financial
"approve an increase in the Company’s authorized share capital"
The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.
beneficial ownership regulatory
"Beneficial ownership is determined in accordance with the rules of the SEC"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
broker non-votes technical
"Broker non-votes occur when brokers that hold their customers’ shares in street name"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
quorum regulatory
"constitutes a quorum for purposes of the Meeting"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
street name technical
"shares are held in “street name” through a broker"
A "street name" is a way that stocks or other financial assets are registered under a broker's name rather than directly in an individual investor's name. This allows for easier buying, selling, and transferring of the assets, much like how a library might hold books on behalf of many readers. For investors, using a street name simplifies transactions and helps maintain privacy, but it also means the broker is the official record holder of ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share-capital increase is ENLV asking shareholders to approve?

Enlivex is asking shareholders to raise authorized share capital from NIS 950,000,000, divided into 9,895,833 ordinary shares, to NIS 9,120,000,000, divided into 95,000,000 ordinary shares, and amend Article 2.1 of the Articles of Association.

When is ENLV's extraordinary meeting, and how can shareholders vote?

The meeting is scheduled for December 4, 2026, at 10:00 a.m. Israel time. Holders may vote by telephone or Internet, or submit a proxy card if they received printed materials; mailed proxies must arrive by December 1, 2026, at 10:00 a.m. Israel time.

What vote is needed to approve ENLV's proposal?

Approval requires the affirmative vote of a majority of ordinary shares represented at the meeting and voting on the proposal, whether in person or by proxy. Abstentions are excluded from that calculation.

What is the quorum for ENLV's December 4, 2026 meeting?

Two or more shareholders holding at least 25% of the voting rights constitute a quorum. If a quorum is not present within an hour, the meeting will be adjourned to the following week at the same day, time and place. At the adjourned meeting, any two shareholders constitute a quorum regardless of voting power.

Who would decide on future ENLV share issuances?

Future issuances would be subject to the board's discretion unless shareholder approval is required under the Companies Law or Nasdaq Listing Rules, to the extent Enlivex cannot or elects not to rely on the home country practice exemption.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: November 2026

 

Commission file number: 001-36578

 

ENLIVEX LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

Extraordinary General Meeting of Shareholders

 

On November 17, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), announced that it will hold an Extraordinary General Meeting of Shareholders of the Company (the “Meeting”) on Friday, December 4, 2026, beginning at 10:00 a.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618. Copies of the notice and proxy statement and the related proxy card are attached to this Report on Form 6-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

 

The information contained in this Report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference into the Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926, File No. 333-286956, File No. 333-292417, File No. 333-294284, File No. 333-295215 and File No. 333-298071), filed with the U.S. Securities and Exchange Commission. 

  

Exhibit No.    
     
99.1   Enlivex Ltd. Notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to be held on December 4, 2026.
99.2   Form of Proxy Card.

  

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Ltd.
  (Registrant)
   
  By: /s/ Oren Hershkovitz
  Name:  Oren Hershkovitz
  Title: Chief Executive Officer

 

Date: November 17, 2026

 

2

 

Exhibit 99.1

 

ENLIVEX LTD.

 

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 4, 2026

 

Dear Shareholder:

 

We cordially invite you to attend an Extraordinary General Meeting of Shareholders (the “Meeting”) of Enlivex Ltd. (the “Company”) to be held on Friday, December 4, 2026, at 10:00 a.m. (Israel time), at the offices of the Company at 14 Einstein Street, Ness Ziona, Israel 7403618.

 

The purpose of the Meeting is to vote on a proposal to approve an increase in the Company’s authorized share capital and to amend the Company’s Articles of Association accordingly.

 

Our Board of Directors recommends that you vote “FOR” the foregoing proposal, which is described in the attached proxy statement.

 

Shareholders of record at the close of business on November 20, 2026 (the “Record Date”) are entitled to notice of and to vote at the Meeting and any adjournments or postponements thereof. You are also entitled to vote at the Meeting if you held ordinary shares through a bank, broker or other nominee that was a shareholder of record at the close of business on the Record Date or which appeared in the participant listing of a securities depository on that date.

 

Whether or not you plan to attend the Meeting, you are urged to vote your shares: (1) by telephone, (2) through the Internet or (3), if you received printed copies of the proxy materials, by promptly completing, dating and signing the enclosed proxy card and mailing it in the enclosed envelope, which requires no postage if mailed within the United States. For specific instructions on how to vote your shares, please refer to the Notice of Internet Availability of Proxy Materials (the “Notice”) that will be mailed to beneficial owners of our ordinary shares, the section titled “How You Can Vote” of the proxy statement, the proxy card or the instructions provided by your broker, bank, trustee or nominee, as applicable.

 

A mailed proxy must be received by our transfer agent or at our registered office in Israel no later than 10:00 a.m. (Israel time) on December 1, 2026, to be validly included in the tally of ordinary shares voted at the Meeting. Return of your proxy does not deprive you of your right to attend the Meeting, to revoke your proxy or to vote your shares in person at the Meeting.

 

The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least twenty-five percent (25%) of the voting rights of the Company constitutes a quorum for purposes of the Meeting. If such quorum is not present within an hour from the time scheduled for the Meeting, the Meeting will be adjourned to the following week, to the same day, time, and place, without it being necessary to notify our shareholders. At such an adjourned meeting, the presence of any two shareholders (in person or by proxy) (regardless of the voting power represented by their ordinary shares) will constitute a quorum.

 

The last date for submitting a request to include a proposal for consideration at the Meeting in accordance with Section 66(b) of the Israeli Companies Law, is November 24, 2026. Shareholders may review the full version of the proposed resolutions in the accompanying proxy statement as well as the accompanying proxy card, at www.proxyvote.com as described in the Notice, via the website of the U.S. Securities and Exchange Commission at www.sec.gov and at the “Investor Relations” portion of our website, which can be found at www.enlivex.com, and also at the Company’s offices, upon prior notice and during regular working hours (14 Einstein Street, Ness Ziona, Israel 7403618; Tel: +972-8-6380301 (phone)), until the date of the Meeting. The information contained on, or accessible through, the foregoing websites is not incorporated by reference in, and does not form a part of, this notice or the accompanying proxy statement.

 

  By Order of the Board of Directors,
   
  /s/ Shai Novik
  Shai Novik
  Executive Chairman of the Board of Directors
 
November 17, 2026

 

 

 

 

ENLIVEX LTD.

14 Einstein Street,

Ness Ziona 7403618

Israel

 

PROXY STATEMENT  

 

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 4, 2026

 

This proxy statement is being furnished in connection with the solicitation of proxies on behalf of the Board of Directors of Enlivex Ltd. (“we,” “us,” “our” or the “Company”) to be voted at an Extraordinary General Meeting of Shareholders (the “Meeting”), or at any adjournment or postponement thereof, pursuant to the accompanying Notice of Extraordinary General Meeting of Shareholders. The Meeting will be held on Friday, December 4, 2026, at 10:00 a.m. (Israel time) at the offices of the Company at 14 Einstein Street, Ness Ziona, Israel 7403618.

 

You are entitled to receive notice of, and vote at, the Meeting if you were a shareholder of record at the close of business on November 20, 2026 (the “Record Date”). Subject to the terms described herein, you are also entitled to vote at the Meeting if you held ordinary shares through a bank, broker or other nominee that was a shareholder of record at the close of business on the Record Date or which appeared in the participant listing of a securities depository on that date. See below “How You Can Vote.”

 

Purpose of the Extraordinary General Meeting

 

At the Meeting, shareholders of the Company will be asked to consider and vote on a proposal to approve an increase in the Company’s authorized share capital and to amend the Company’s Articles of Association accordingly.

 

We are not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, the person designated as proxy intends to vote on such matters in accordance with her best judgment in the best interests of the Company.

 

Board Recommendation

 

Our Board of Directors unanimously recommends that you vote “FOR” the above proposal, which is described in greater detail elsewhere in this Proxy Statement.

 

Quorum and Adjournment

 

The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least twenty-five percent (25%) of the voting rights of the Company constitutes a quorum for purposes of the Meeting. If such quorum is not present within an hour from the time scheduled for the Meeting, the Meeting will be adjourned to the following week, to the same day, time and place, without it being necessary to notify our shareholders. At such an adjourned meeting, the presence of any two shareholders (in person or by proxy) (regardless of the voting power represented by their ordinary shares) will constitute a quorum.

 

Abstentions and broker non-votes will be counted for purposes of determining the presence of a quorum, but they will not have an effect on the outcome of the proposal. Broker non-votes occur when brokers that hold their customers’ shares in street name sign and submit proxies for such shares (in which case they are considered present for purposes of determining the presence of a quorum at the Meeting) but do not have the discretionary authority to vote on the proposal. Brokers that have not received voting instructions from their customers may vote such shares, as the holders of record, on “routine” matters but not on “non-routine” matters. The proposal constitutes a “routine” matter.

 

Unsigned or unreturned proxies, including those not returned by banks, brokers, or other record holders, will not be counted for quorum or voting purposes.

 

2

 

 

How You Can Vote

 

●Voting in person. If your shares are registered directly in your name with our transfer agent (i.e., you are a “registered shareholder”), you may attend and vote in person at the Meeting. If you are a beneficial owner of shares registered in the name of your broker, bank, trustee or nominee (i.e., your shares are held in “street name”), you are also invited to attend the Meeting; however, to vote in person at the Meeting as a beneficial owner, you must first obtain a “legal proxy” from your broker, bank, trustee or nominee, as the case may be, authorizing you to do so. If you vote by telephone or Internet, there is no need to vote again at the Meeting unless you wish to revoke and change your vote.

 

  ● Voting by mailing your proxy. If you have received printed copies of the proxy materials, you may submit your proxy by mail by completing, signing and mailing the enclosed proxy card in the enclosed, postage-paid envelope, or, for shares held in street name, by following the voting instructions provided by your broker, bank, trustee or nominee. The proxy must be received by our transfer agent or at our registered office in Israel by no later than 10:00 a.m. Israel time, on December 1, 2026, to be validly included in the tally of ordinary shares voted at the Meeting. Upon the receipt of a properly signed and dated proxy in the form enclosed, the person named as proxy therein will vote the ordinary shares represented thereby in accordance with the instructions of the shareholder indicated thereon, or if no direction is indicated, in accordance with the recommendations of our Board of Directors.

 

●Voting by telephone or Internet. If your shares are held in an account at a brokerage firm or bank or registered directly in your name with our transfer agent, you may vote those shares by accessing the Internet website address, or by calling the telephone number, specified in the Notice of Internet Availability of Proxy Materials, the instructions provided by your broker, bank, trustee or nominee or on your proxy card (as applicable), instead of completing and signing the proxy itself. If your shares are held in an account at a brokerage firm or bank, you may also call the telephone number specified in the instructions provided by your broker, bank, trustee or nominee. Submitting a telephonic or Internet proxy will not affect your right to vote at the Meeting should you decide to attend the Meeting. The telephone and Internet voting procedures are designed to authenticate shareholders’ identities, to allow shareholders to give their voting instructions, and to confirm that shareholders’ instructions have been recorded properly. The accompanying proxy card provides instructions on how to vote via telephone and the Internet.

 

Vote Required for Approval of the Proposal

 

Each outstanding ordinary share held by a shareholder is entitled to one vote on each matter submitted to a vote of our shareholders.

 

The approval of the proposal requires the affirmative vote of a majority of the ordinary shares represented at the Meeting, whether in person or by proxy, and voting on the proposal (excluding abstentions).

 

Change or Revocation of Proxy

 

If you are a shareholder of record, you may change your vote at any time prior to the exercise of authority granted in the proxy by delivering a written notice of revocation to us, by granting a new proxy bearing a later date, or by attending the Meeting and voting in person. Attendance at the Meeting will not cause your previously granted proxy to be revoked unless you specifically so request. You may also revoke your proxy and change your vote at any time before the final vote at the Meeting by voting again via the Internet or by telephone, as applicable.

 

If your shares are held in “street name” through a broker, bank, trustee or other nominee, you may change your vote by submitting new voting instructions to your broker, bank, trustee or nominee or, if you have obtained a legal proxy from your broker, bank, trustee or nominee giving you the right to vote your shares, by attending the Meeting and voting in person.

 

Solicitation of Proxies

 

All expenses of this solicitation will be borne by the Company. In addition to the solicitation of proxies by mail, directors, officers and employees of the Company, without receiving additional compensation therefor, may solicit proxies by telephone, email, in person or by other means. Brokerage firms, nominees, fiduciaries and other custodians have been requested to forward proxy solicitation materials to the beneficial owners of shares of the Company held of record by such persons, and the Company will reimburse such brokerage firms, nominees, fiduciaries and other custodians for reasonable out-of-pocket expenses incurred by them in connection therewith.

 

3

 

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth certain information as of November 10, 2026 (unless otherwise indicated below) regarding the beneficial ownership by: (i) each person known to us to beneficially own more than 5% of our outstanding ordinary shares, based on public filings or information available to us; (ii) each of our current directors and executive officers; and (iii) all of our current directors and executive officers as a group. The percentage of ordinary shares beneficially owned is based on 1,532,077 ordinary shares issued and outstanding as of November 10, 2026.

 

Beneficial ownership is determined in accordance with the rules of the U.S. Securities and Exchange Commission (“SEC”) and is generally based on whether a person has voting or investment power with respect to the securities. Ordinary shares of the Company that may be acquired by an individual or group pursuant to the exercise of the Company’s outstanding options, restricted share units (“RSUs”), warrants or other rights held by such individual or group that are exercisable or will become exercisable within 60 days of November 10, 2026 are deemed beneficially owned by such individual or group, and such shares are additionally deemed outstanding for the purposes of computing the percentage of ordinary shares beneficially owned by such individual or group, but are not deemed outstanding for purposes of computing the percentage of ordinary shares beneficially owned by any other individual or group shown in the table.

 

   Number of Ordinary Shares Beneficially Owned   Percentage of Ordinary Shares Beneficially Owned 
5% Shareholders        
Sobrinia Ltd. (1)   90,735    5.88%
Heaven Consulting Corp   78,334    5.11%
Directors and Officers          
Shai Novik (2)   33,825    2.20%
Roger Pomerantz, M.D. (3)   634    * 
Avri Havron, Ph.D. (4)   1,001    * 
Gili Hart, Ph.D. (5)   323    * 
Matteo Renzi   —    — 
Oren Hershkovitz (6)   1,596    * 
Shachar Shlosberger (7)   473    * 
Einat Galmidi (8)   573    * 
Amor-Baroukh Veronik (9)   327    * 
All directors and executive officers as a group (9 persons)   38,752    2.52%

 

* Less than 1% of our outstanding ordinary shares.

 

(1) Includes 12,274 ordinary shares issuable under currently exercisable pre-funded warrants.

 

4

 

 

(2) Includes 4,766 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 554 options expire in December 2033 and have an exercise price of $646, 606 options expire in December 2033 and have an exercise price of $1,493, 1,041 options expire in May 2030 and have an exercise price of $879, 1,041 options expire in May 2031 and have an exercise price of $2,935 and 1,524 options expire in November 2032 and have an exercise price of $1,282.
   
(3) Includes 625 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, which expire in November 2032 and have an exercise price of $1,432, and 3 RSUs that shall vest within 60 days from November 10, 2026.

 

(4) Includes 235 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 221 options expire in December 2033 and have an exercise price of $646 and 14 options expire in November 2032 and have an exercise price of $1,282, and 1 RSU that shall vest within 60 days from November 10, 2026.
   
(5) Includes 291 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 277 options expire in December 2033 and have an exercise price of $646 and 14 options expire in November 2032 and have an exercise price of $1,282, and 1 RSU that shall vest within 60 days from November 10, 2026.
   
(6) Includes 875 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 625 options expire in December 2033 and have an exercise price of $1,966 and 250 options expire in November 2032 and have an exercise price of $1,282.
   
(7) Includes 120 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026.
   
(8) Includes 146 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026.
   
(9) Includes 174 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026.

 

5

 

 

PROPOSAL 1

APPROVAL OF AN INCREASE IN THE COMPANY’S AUTHORIZED SHARE CAPITAL AND A CORRESPONDING AMENDMENT TO THE COMPANY’S ARTICLES OF ASSOCIATION

 

Background

 

The Company’s authorized share capital is currently NIS 950,000,000, divided into 9,895,833 ordinary shares with a nominal value of NIS 96.0 each. As of November 10, 2026, 1,532,077 ordinary shares were issued and outstanding. In addition, as of such date, 77,867 ordinary shares were reserved for issuance under our Global Share Incentive Plan (2014) and Global Share Incentive Plan (2019) (including shares underlying outstanding options and RSUs), and 30,782 ordinary shares were reserved for issuance upon the exercise of outstanding warrants. Accordingly, as of such date, 8,255,107 ordinary shares remained unissued, unreserved, and available for future issuances.

  

Under the Companies Law, a company may not issue shares in excess of its authorized share capital. The Company seeks to increase its authorized share capital to help ensure that it can support its corporate purposes and future business needs as they arise, including, without limitation, potential public and private offerings of the Company’s ordinary shares, debt conversions or repayments, and other corporate purposes, which may include, without limitation, potential strategic transactions, such as mergers (including reverse mergers or similar business combinations), spin-offs, separations or other reorganizations of all or part of the Company’s business, acquisitions of other companies or assets, or other transactions that may involve the issuance of ordinary shares, as well as for purposes of equity-based compensation grants under existing or any future equity-based incentive plans adopted by the Company.  Any such future issuances will be subject to the discretion of our Board of Directors, unless shareholder approval is required under the Companies Law and/or under the Nasdaq Listing Rules (to the extent the Company is not permitted to, or elects not to, rely on the home country practice exemption under such rules).

 

Accordingly, at the Meeting, and as recommended by our Board of Directors, shareholders will be asked to approve an increase in the Company’s authorized share capital from NIS 950,000,000, divided into 9,895,833 ordinary shares with a nominal value of NIS 96.0 each, to NIS 9,120,000,000, divided into 95,000,000 ordinary shares with a nominal value of NIS 96.0 each, and to amend Article 2.1 of the Company’s Articles of Association accordingly to reflect this change.

 

The proposed increase in our authorized share capital would not affect the rights of the holders of currently outstanding ordinary shares. However, the possible future issuance of ordinary shares, or securities convertible into, or exercisable for, ordinary shares, could affect our current shareholders in a number of ways, including: (i) diluting the voting power of current holders of ordinary shares; (ii) diluting the market price of the ordinary shares, to the extent that new ordinary shares are issued and sold at prices below the current trading price of the existing ordinary shares, or, in the case of convertible securities, to the extent that such securities are convertible into, or exercisable for, ordinary shares at prices below current trading prices; and (iii) diluting the book value per share of the outstanding ordinary shares.

 

Proposal

 

It is therefore proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, to approve the increase in the Company’s authorized share capital from NIS 950,000,000 divided into 9,895,833 ordinary shares with a nominal value of NIS 96.0 each, to NIS 9,120,000,000 divided into 95,000,000 ordinary shares with a nominal value of NIS 96.0 each, and to amend Article 2.1 of the Company’s Articles of Association accordingly.”

 

Approvals Required

 

See “Vote Required for Approval of the Proposal” above.

 

6

 

 

Board Recommendation

 

Our Board of Directors recommends a vote “FOR” the approval of the increase in the Company’s authorized share capital and the corresponding amendment to the Company’s Articles of Association.

 

OTHER BUSINESS

 

The Board of Directors is not aware of any business to be transacted at the Meeting other than those described in this proxy statement. If any other matters are properly brought before the Meeting, it is intended that the person named as proxy in the enclosed form of proxy will vote upon such matters, pursuant to her discretionary authority, in accordance with her best judgment in the best interests of the Company.

 

ADDITIONAL INFORMATION

 

We are subject to the information reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), applicable to foreign private issuers, and we fulfill the obligations with respect to those requirements by filing reports with the SEC. Our SEC filings are available to the public on the SEC’s website at www.sec.gov and under the “Investor Relations” section of our website at www.enlivex.com. The contents of the foregoing websites do not form part of this Proxy Statement.

 

As a foreign private issuer, we are exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements. The circulation of this proxy statement and related notice should not be taken as an admission that we are subject to those proxy rules.

 

  By Order of the Board of Directors
   
   
  Shai Novik
  Executive Chairman of the Board of Directors

 

November 17, 2026

 

 

7

 

 

Exhibit 99.2

 

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN.

EXCEPT AS MENTIONED OTHERWISE IN THE PROXY STATEMENT AND BELOW ON THIS PROXY, IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE PROPOSAL HEREIN.

Please mark your vote as in this example ☒    

PROPOSAL NO. 1: To approve an increase in the Company’s authorized share capital and to amend the Company’s Articles of Association accordingly. FOR AGAINST ABSTAIN

☐ 

 

☐ ☐

The undersigned hereby acknowledges receipt of the Notice of the Extraordinary General Meeting, revokes any proxy or proxies heretofore given to vote upon or act with respect to the undersigned’s shares and hereby ratifies and confirms all that the proxies, their substitutes, or any of them, may lawfully do by virtue hereof.
____________________________   __________________________________   _______________________
(NAME OF SHAREHOLDER)   (SIGNATURE OF SHAREHOLDER)   (DATE)

 

ENLIVEX LTD.

 

Extraordinary General Meeting of Shareholders to be held on December 4, 2026

 

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

 

The undersigned shareholder of Enlivex Ltd. (the “Company”) hereby appoints Ms. Shachar Shlosberger, the true and lawful attorney, agent and proxy of the undersigned, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at an Extraordinary General Meeting of Shareholders of the Company, to be held at the offices of the Company at 14 Einstein Street, Ness Ziona 7403618, Israel on Friday, December 4, 2026 at 10:00 a.m. (Israel time), and all adjournments and postponements thereof.

 

(CONTINUED AND TO BE SIGNED ON REVERSE SIDE) 

  

Filing Exhibits & Attachments

2 documents

Keep reading